Loading...
By Amy Orciari Herman
Edited by André Sofair, MD, MPH
A polypill containing fixed doses of four drugs reduces risk for cardiovascular events, according to an industry-supported study in the Lancet.
Nearly 7000 adults in Iran were randomized to receive either a daily polypill — comprising hydrochlorothiazide, aspirin, atorvastatin, and enalapril — plus lifestyle counseling, or lifestyle counseling alone. (Polypill recipients who developed a cough were switched to a different polypill that contained valsartan instead of enalapril.) Participants were followed for up to 5 years.
The primary outcome — incidence of major cardiovascular events — occurred significantly less often in the polypill group (5.9% vs. 8.8% of participants). The risk reduction was significant in those with and those without pre-existing cardiovascular disease. Those with high adherence saw an even greater reduction in CV events.
Dr. Harlan Krumholz of NEJM Journal Watch Cardiology commented: "In an era of precision medicine, this one-size-fits-all intervention markedly reduced cardiovascular risk in a rural population. For advocates, it's a great proof of concept; for skeptics, it feels unsatisfying, as many questions remain. It may be most appropriate for now in resource-poor settings where options are limited."
Comment
LINK(S):
Lancet article (Free abstract)
Background: NEJM Journal Watch Cardiology coverage of a polypill & medication adherence (Your NEJM Journal Watch registration required)